Literature DB >> 19796080

Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides.

Dennis M Klinman1, Debbie Tross, Sven Klaschik, Hidekazu Shirota, Takeshi Sato.   

Abstract

Synthetic oligodeoxynucleotides (ODN) capable of "neutralizing" or "inhibiting" immune responses have been described. This review will focus on the properties of phosphorothioate ODN that mimic the immunosuppressive activity of the repetitive TTAGGG motifs present in mammalian telomeres. These TTAGGG multimers block the production of pro-inflammatory and T helper type 1 cytokines elicited when immune cells are activated by a wide variety of Toll-like receptor ligands, polyclonal activators, and antigens. Several mechanisms contribute to the suppressive activity of such ODN. Ongoing microarray studies indicate that suppressive ODN interfere with the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT4, thereby blocking the inflammation mediated by STAT-associated signaling cascades. In animal models, suppressive ODN can be used to prevent or treat diseases characterized by persistent immune activation, including collagen-induced arthritis, inflammatory arthritis, systemic lupus erythematosus, silicosis, and toxic shock. These findings suggest that TTAGGG multimers may find broad use in the treatment of diseases characterized by over-exuberant/persistent immune activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796080     DOI: 10.1111/j.1749-6632.2009.04970.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  STAT1 regulates MD-2 expression in monocytes of sepsis via miR-30a.

Authors:  Yanhong Wang; Tiehua Li; Benquan Wu; Hui Liu; Jinmei Luo; Dingyun Feng; Yunfeng Shi
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

3.  Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

4.  Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Duc H Do; Veronica M Holmes; Mary K Howett; Mark G Lewis; Alina C Boesteanu; Sefik S Alkan; Peter D Katsikis
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation.

Authors:  Christian Bode; Jing Wang; Dennis M Klinman
Journal:  Int Immunopharmacol       Date:  2014-10-12       Impact factor: 4.932

6.  Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.

Authors:  Chunsong Yu; Myunggi An; Evan Jones; Haipeng Liu
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

7.  Suppressive oligonucleotides inhibit inflammation in a murine model of mechanical ventilator induced lung injury.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

8.  Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes.

Authors:  Zhuo Wang; Zhong Deng; Nadia Dahmane; Kevin Tsai; Pu Wang; Dewight R Williams; Andrew V Kossenkov; Louise C Showe; Rugang Zhang; Qihong Huang; José R Conejo-Garcia; Paul M Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 10.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Chary López-Pedrera; Maria Ángeles Aguirre; Nuria Barbarroja; Maria José Cuadrado
Journal:  J Biomed Biotechnol       Date:  2010-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.